New use of anti-impaludism medicament hydroxyl chloroquine

A technology of hydroxychloroquine and new use, applied in the new use field of antimalarial drug hydroxychloroquine, can solve problems such as incurability

CN101428025AInactive Publication Date: 2009-05-13FOURTH MILITARY MEDICAL UNIVERSITY
0 Cites 13 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2009-05-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the novel usage of an antimalarial medicine, in particular to the novel usage of hydroxychloroquine having sensitivity enhancing effect on various chemical anti-multiple myeloma medicaments. The novel usage is characterized in the application of hydroxychloroquine in treatment of multiple myeloma through chemotherapeutic medicaments. The hydroxychloroquine can obviously enhance the killing activity of chemotherapeutic medicines such as doxorubicine, epidoxorubicin, cis-platinum and mitoxantrone to multiple myeloma cells, and the killing activity thereof is realized by inhibiting the myeloma cell autophagy signals by hydroxychloroquine. Hydroxychloroquine can induce the quantity of the autophagy lysosomes of the multiple myeloma cells to be increased and the expression of the autophagy-associated albumen LC3-II to be increased.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a new application of an antimalarial drug, in particular to a new application of hydroxychloroquine which has a sensitizing effect on various chemical anti-multiple myeloma drugs. Background technique

[0002] Multiple myeloma (MM) is a lethal malignant plasma cell tumor derived from memory B cells or plasma cells, mainly affecting the elderly, with a median age of onset of 60 years. Clinically, MM is incurable, but its survival is highly heterogeneous (several weeks to more than 10 years). In view of the fact that the most critical factor affecting the survival of MM is the formation of drug resistance, it is necessary to continuously search for and develop specific and efficient drug resistance reversal agents aimed at the drug resistance mechanism of tumor cells. The survival period is particularly important. Contents of the invention

[0003] The purpose of the present invention is to provide a new application of antima...

Examples

Embodiment Construction

[0017] In order to better understand the essence of the present invention, the following experiments and results will be used to further illustrate the killing activity of multiple myeloma cells by hydroxychloroquine enhancing doxorubicin and other conventional chemotherapy drugs and its mechanism. It should be noted that the following examples are only used to illustrate the implementation of the present invention, and do not limit the implementation scope of the present invention.

[0018] 1. Experimental reagents and cells

[0019] Human myeloma cell line H929 was cultured in RPMI1640 medium with 10% fetal bovine serum in 5% CO 2 , 10% fetal bovine serum, saturated humidity, cultured in a 37°C incubator, subcultured once every 2-3 days, and the cells were in the exponential growth phase during the experiment. Hydroxychloroquine (0.1 / tablet) (product of Shanghai Zhongxi Pharmaceutical Co., Ltd.), fully dissolved in water for injection, centrifuged at 12,000 rpm, subpackaged...